Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats

Journal of Hypertension

Volumn 30, Issue 10, 2012, Pages 1992-1999

  Konno, Satomi ^a   Hirooka, Yoshitaka ^a   Kishi, Takuya ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

angiotensin II; brain; hypertension; obesity; sympathetic nervous system

Indexed keywords

ADIPONECTIN; APOCYNIN; GLUCOSE; INSULIN; LOSARTAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TELMISARTAN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BRAIN REGION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIET; DRUG EFFICACY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERTENSION; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID DIET; MICROINJECTION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ROSTRAL VENTROLATERAL MEDULLA; SYSTOLIC BLOOD PRESSURE;

EID: 84866535444     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328357fa98     Document Type: Article

References (51)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
2. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28:629-636.
3. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-414.
4. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006; 48:787-796.
5. Raumouni K, Correla ML, Haynes WG, Mark AL. Obesity associated hypertension: new insights into mechanisms. Hypertension 2005; 45:9-14.
6. Grassi G. Adrenergic overdrive as the link among hypertension, obesity, and impaired thermogenesis: lights and shadows. Hypertension 2007; 49:5-6.
7. Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res 2006; 29:839-847.
8. Landsberg L. Insulin-mediated sympathetic stimulation role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001; 19:523-528.
9. Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994; 74:323-364.
10. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7:335-346.
11. Stocker SD, Meador R, Adams JM. Neurons of the rostral ventrolateral medulla contribute to obesity-induced hypertension in rats. Hypertension 2007; 49:640-646.
12. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 2004; 109:3257-3262.
13. Kishi T, Hirooka Y, Konno S, Ogawa K, Sunagawa K. Angiotensin II type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase/extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in stroke-prone spontaneously hypertensive rats. Hypertension 2010; 55:291-297.
14. Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation. Pathogenesis of hypertension and therapeutic aspects. Circ J 2010; 74:827-835.
15. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001; 37:554-560.
16. Smith AD, Brands MW, Wang MH, Dorrance AM.Obesity-induced hypertension develops in young rats independently of the renin-angiotensin-aldosterone system. Exp Biol Med (Maywood) 2006; 231:282-287.
17. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111:1448-1454.
18. Zhang X, Dong X, Ren J, Driscoll MJ, Culver B. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 2005; 191:318-325.
19. Nagae A, Fujita M, Kawarazaki H, Matsui H, Ando K, Fujita T. Sympatho-excitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation 2009; 119:978-986.
20. Kishi T, Hirooka Y, Ogawa K, Konno S, Sunagawa K. Calorie restriction inhibits sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of obesity-induced hypertensive rats. Clin Exp Hypertens 2011; 33:245-250.
21. Gao XY, Zhang F, Han Y, Wang HJ, Zhang Y, Guo R, Zhu GQ. AT1 receptor in rostral ventrolateral medulla mediating blunted barorecep-tor reflex in spontaneously hypertensive rats. Acta Pharmacol Sin 2004; 25:1433-1438.
22. Koga Y, Hirooka Y, Araki S, Nozoe M, Kishi T, Sunagawa K. High salt intake enhances blood pressure increase during development of hypertension via oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertens Res 2008; 31:2075-2083.
23. Ito S, Komatsu K, Tsukamoto K, Kanmatsuse K, Sved AF. Ventrolateral medulla AT1 receptor support blood pressure in hypertensive rats. Hypertension 2002; 40:552-559.
24. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298:62-70.
25. Wang JM, Tan J, Leenen FHH. Central nervous system blockade by peripheral administration of AT1 receptor blockers. J Cardiovasc Pharmacol 2003; 41:593-599.
26. Lin Y, Matsumura K, Kagiyama S, Fukuhara M, Fujii K, Iida M. Chronic administration of olmesartan attenuates the exaggerated pressor response to glutamate in the lostral ventrolateral medulla of SHR. Brain Res 2005; 1058:161-166.
27. Lin Y, Tsuchihashi T, Kagiyama S, Matsumura K, Abe I. The influence of chronic antihypertensive treatment on the central pressor response in SHR. Hypertens Res 2001; 24:173-178.
28. Tsuchihashi T, Kagiyama S, Matsumura K, Abe I, Fujishima M. Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. J Hypertens 1999; 17:917-922.
29. Pelosch N, Hosomi N, Ueno M, Masugata H, Murao K, Hitomi H, et al. Systemic candesartan reduces brain angiotensin II via downregulation of brain renin-angiotensin system. Hypertens Res 2010; 33:161-164.
30. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihyper-tensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
31. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al., Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32:3-107.
32. Nozoe M, Hirooka Y, Koga Y, Araki S, Konno S, Kishi T, et al. Mitochondria-derived reactive oxygen species mediate sympathoexci-tation induced by angiotensin II in the rostral ventrolateral medulla. J Hypertens 2008; 26:2176-2184.
33. Benson SC, Pershadsingh HA, Ho CL, Chittinoyina A, Desai P, Pravanec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43:993-1002.
34. De Cavanagh EM, Felder LF, Felder MD, Stella IY, Toblli JE, Inserra F. Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol. Am J Hypertens 2010; 23:1318-1325.
35. Marschall FH, Clark SA, Michel AD, Barnes JC. Binding of angiotensin antagonist to rat liver and brain membranes measured ex vivo. Br J Pharmacol 1993; 109:760-764.
36. Toyama K, NakamuraT, Kataoka K, Yasuda O, FukudaM, Tokutomi Y, et al. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-g-dependent activity. Biochem Biophys Res Commun 2011; 410:508-513.
37. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302:237-243.
38. Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya I, et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008; 9:179-186.
39. Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12:1-7.
40. Chan SH, Wu KL, Kung PS, Chan JY. Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension 2010; 55:1444-1453.
41. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type I receptor blockers induce peroxisome proliferator-activated receptor-g activity. Circulation 2004; 109:2054-2057.
42. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 2004; 95:210-216.
43. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, Davisson RL. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 2002; 91:1038-1045.
44. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol 2004; 287:R943-R949.
45. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004; 43:48-56.
46. Lauterio TJ, Davies MJ, DeAngelo M, Peyser M, Lee J. Neuropeptide Y expression and endogenous leptin concentrations in a dietary model of obesity. Obes Res 1999; 7:498-505.
47. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F. Protective effect of long-term angiotensin II inhibition. Am J Physiol 2007; 293:H1351-H1358.
48. Kamari Y, Harari A, Shaish A, Peleg E, Sharabi Y, Harats D, Grossman E. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyper-lipidemic rats. Hypertens Res 2008; 31:135-140.
49. Khan AH, Lmig JD. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am J Hypertens 2011; 24:816-821.
50. Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, et al. Attenuation of diet-induced wight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146:3481-3489.
51. Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36:857-870.